Curis (NASDAQ: CRIS) is a speculative stock -- no approved product and no revenue -- that, in former markets, would sell for $10 - $12. It is now around a buck and a half, after doubling in the past few months.
CRIS focuses on cancer treatments, and is partnered with Genentech/Roche. It has a new therapy for basal cell carcinoma in mid-stage trials. The results appear very promising. In fact, they are so promising that Genentech is treating this as the last trial needed before seeking FDA approval.
This stock is a potential 10- to 20-bagger with an FDA approval in 2011 or so. And the company is on the verge of licensing a new molecule that could be a big catalyst for the stock in the short term.
Your best strategy for life-changing profits?
Buy CRIS now. (In the interest of full disclosure, I own a lot of CRIS.)
Next: Biotech Stock #5
Newspaper ad revenue of 28%, 8 quarters of double-digit drops
Closing Bell: Earnings working against stocks (BCRX, DELL, DHI, INTC, LEAP, PCS)
Chasing Value: E-Trade, a word of caution
